Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amarin Corp Ads (AMRN)

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,373,722
  • Shares Outstanding, K 391,058
  • Annual Sales, $ 429,760 K
  • Annual Income, $ -22,650 K
  • 60-Month Beta 2.58
  • Price/Sales 4.42
  • Price/Cash Flow N/A
  • Price/Book 3.98
Trade AMRN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.00
  • Number of Estimates 6
  • High Estimate 0.04
  • Low Estimate -0.03
  • Prior Year 0.02
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.75 +27.79%
on 12/29/20
6.32 -3.96%
on 01/15/21
+0.80 (+15.18%)
since 12/15/20
3-Month
3.96 +53.28%
on 11/11/20
6.32 -3.96%
on 01/15/21
+1.02 (+20.20%)
since 10/15/20
52-Week
3.36 +80.65%
on 09/24/20
21.82 -72.18%
on 01/21/20
-13.33 (-68.71%)
since 01/15/20

Most Recent Stories

More News
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference

Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on...

JPM : 138.64 (-1.79%)
AMRN : 6.07 (-0.98%)
Amarin (AMRN) Surges: Stock Moves 9% Higher

Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

AMRN : 6.07 (-0.98%)
BPMC : 100.99 (-1.48%)
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

AMRN : 6.07 (-0.98%)
VASCEPA(R) (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020

Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on VASCEPA(R) (icosapent ethyl) will be presented during the National Lipid Association...

AMRN : 6.07 (-0.98%)
Amarin Files Patent Infringement Lawsuit Against Hikma

Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma's U.S. affiliate. The lawsuit...

HKMPF : 35.4000 (-2.21%)
AMRN : 6.07 (-0.98%)
Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)

Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler's 32 Annual...

AMRN : 6.07 (-0.98%)
With Growing Incidence of Brain Cancer The Brain Tumor Drug Market Could Reach $3.4 Billion in 2022

, /PRNewswire/ -- With the increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure, the demand of diagnosis and treatment of brain tumors...

CNSP : 1.9200 (+2.13%)
AMRN : 6.07 (-0.98%)
ATHE : 1.6000 (-9.09%)
BMY : 66.54 (+0.79%)
NVCR : 167.55 (-6.37%)
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures

HLS.TO : 16.95 (+2.67%)
AMRN : 6.07 (-0.98%)
More Comprehensive Diagnostics are Needed as Cases Surge Once More

, /PRNewswire/ -- The pandemic is in full swing once again; the daily U.S. death toll crossed the 2,000 mark on Wednesday as weeks of rising infection rates are now manifesting in mortality numbers not...

TOMDF : 0.0679 (-3.00%)
AMRN : 6.07 (-0.98%)
INO : 9.66 (+3.09%)
CODX : 10.54 (+3.74%)
ALT : 12.93 (-4.72%)
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences

Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences...

AMRN : 6.07 (-0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

3rd Resistance Point 6.54
2nd Resistance Point 6.43
1st Resistance Point 6.25
Last Price 6.07
1st Support Level 5.96
2nd Support Level 5.85
3rd Support Level 5.67

See More

52-Week High 21.82
Fibonacci 61.8% 14.77
Fibonacci 50% 12.59
Fibonacci 38.2% 10.41
Last Price 6.07
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar